Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.57T
24h Vol:
$3.94B
Dominance:
MSFT:5.14%
Stocklytics Platform
BETA
Instrument logo  SERA

Sera Prognostics, Inc.

SERA
65 / 100
High Growth
$8.54arrow_drop_down-0.98%-$0.08

Performance History

Stocklytics logo
Key Stats
Open$8.45
Prev. Close$8.60
EPS-1.23
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$257.22M
PE Ratio-
LOWHIGH
Day Range8.25
8.80
52 Week Range1.52
9.97
Ratios
P/B Ratio3.52
Revenue-
Operating M. %-19,485.72%
Earnings$0.00
Earnings Growth %13.86%
EBITDA Margin %-
ROE %-41.70%
EPS-1.23

Score Breakdown

65vs 53. Market Avg.

All Score 65 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

SERAMARKET
Value2639
Quality4940
Ownership3319
Growth8046
Dividends-37
check_circle

Sera Prognostics, Inc.'s Price growth average in the last 3 years of 46.09% is great compared to market average of 6.06%. This indicates SERA could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$766.50
24H (%)arrow_drop_down-0.70%
24H ($)-$5.41
MARKET CAP$728.73B
PRICE$520.58
24H (%)arrow_drop_down-0.90%
24H ($)-$4.74
MARKET CAP$481.60B
PRICE$160.46
24H (%)arrow_drop_down-0.20%
24H ($)-$0.32
MARKET CAP$386.43B
PRICE$128.81
24H (%)arrow_drop_down-0.02%
24H ($)-$0.03
MARKET CAP$326.27B

About Sera Prognostics, Inc. (SERA)

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sector
Healthcare
Industry
Diagnostics & Research
CEO
Ms. Evguenia Lindgardt M.B.A.
Headquarters
Salt Lake City
Employees
87
Exchange
NASDAQ
add Sera Prognostics, Inc. to watchlist

Keep an eye on Sera Prognostics, Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Sera Prognostics, Inc.'s (SERA) price per share?

The current price per share for Sera Prognostics, Inc. (SERA) is $8.54. The stock has seen a price change of -$0.08 recently, indicating a -0.98% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Sera Prognostics, Inc. (SERA)?

For Sera Prognostics, Inc. (SERA), the 52-week high is $9.97, which is 16.68% from the current price. The 52-week low is $1.52, the current price is 462.17% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Sera Prognostics, Inc. (SERA) a growth stock?

Sera Prognostics, Inc. (SERA) has shown an average price growth of 46.09% over the past three years. It has received a score of 92 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Sera Prognostics, Inc. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Sera Prognostics, Inc. (SERA) stock price performance year to date (YTD)?

As of the latest data, Sera Prognostics, Inc. (SERA) has a year-to-date price change of 43.61%. Over the past month, the stock has experienced a price change of 23.66%. Over the last three months, the change has been 342.75%. Over the past six months, the figure is 361.89%.

question_mark
Is Sera Prognostics, Inc. (SERA) a profitable company?

Sera Prognostics, Inc. (SERA) has a net income of -$38.06M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 25.76% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -19.49K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 23.13%, providing insight into the company's sales performance and growth. The gross profit is $85K. Operating income is noted at -$41.39M. Furthermore, the EBITDA is -$40M.

question_mark
What is the market capitalization of Sera Prognostics, Inc. (SERA)?

Sera Prognostics, Inc. (SERA) has a market capitalization of $270.43M. The average daily trading volume is 211.03K, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.